FDA Issues Draft Guidance for Gene Therapy Genome Editing Safety
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Illumina has announced an 18-month roadmap for NovaSeq X, featuring a 40% output increase to 35 billion reads, faster turnaround times, new flow cell options, and the introduction of Q70 quality scores.
The BLOODPAC Consortium has released new analytical validation standards for liquid biopsy MRD tests, offering industry-wide protocols for tumor-informed ctDNA assay development, as detailed in JCO Precision Oncology.